Cargando…
BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma
BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify ratio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264287/ https://www.ncbi.nlm.nih.gov/pubmed/28122578 http://dx.doi.org/10.1186/s12943-017-0587-x |
_version_ | 1782500074791632896 |
---|---|
author | Parasramka, Mansi Yan, Irene K. Wang, Xue Nguyen, Phuong Matsuda, Akiko Maji, Sayantan Foye, Catherine Asmann, Yan Patel, Tushar |
author_facet | Parasramka, Mansi Yan, Irene K. Wang, Xue Nguyen, Phuong Matsuda, Akiko Maji, Sayantan Foye, Catherine Asmann, Yan Patel, Tushar |
author_sort | Parasramka, Mansi |
collection | PubMed |
description | BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies. METHODS: The impact of BAP1 expression on sensitivity to therapeutic agents was evaluated in CCA cells with a 7-fold difference in BAP1 expression (KMBC-low, HuCCT1-high) and genetically engineered haplo-insufficient BAP1 knockout cells. We also identified long non-coding RNA genes associated with loss of BAP1 and their role in therapeutic sensitivity. RESULTS: Sensitivity to gemcitabine was greater in low BAP1 expressing or BAP1 knockout cells compared with the high BAP1 expressing cells or control haplo-insufficient cells respectively. Similar results were observed with TSA, olaparib, b-AP15 but not with GSK126. A differential synergistic effect was observed in combinations of gemcitabine with olaparib or GSK126 in KMBC cells and TSA or bAP15 in HuCCT1 cells, indicating BAP1 dependent target-specific synergism and sensitivity to gemcitabine. A BAP1 dependent alteration in expression of lncRNA NEAT-1 was identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1 was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Exogenous modulation of NEAT-1 and/or BAP1 expression altered tumor cell phenotype and modulated sensitivity to gemcitabine. CONCLUSIONS: NEAT-1 is a downstream effector of gemcitabine sensitivity in CCA. The expression of BAP1 is a determinant of sensitivity to therapeutic drugs that can be exploited to enhance responses through combination strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0587-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5264287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52642872017-01-30 BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma Parasramka, Mansi Yan, Irene K. Wang, Xue Nguyen, Phuong Matsuda, Akiko Maji, Sayantan Foye, Catherine Asmann, Yan Patel, Tushar Mol Cancer Research BACKGROUND: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1 expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies. METHODS: The impact of BAP1 expression on sensitivity to therapeutic agents was evaluated in CCA cells with a 7-fold difference in BAP1 expression (KMBC-low, HuCCT1-high) and genetically engineered haplo-insufficient BAP1 knockout cells. We also identified long non-coding RNA genes associated with loss of BAP1 and their role in therapeutic sensitivity. RESULTS: Sensitivity to gemcitabine was greater in low BAP1 expressing or BAP1 knockout cells compared with the high BAP1 expressing cells or control haplo-insufficient cells respectively. Similar results were observed with TSA, olaparib, b-AP15 but not with GSK126. A differential synergistic effect was observed in combinations of gemcitabine with olaparib or GSK126 in KMBC cells and TSA or bAP15 in HuCCT1 cells, indicating BAP1 dependent target-specific synergism and sensitivity to gemcitabine. A BAP1 dependent alteration in expression of lncRNA NEAT-1 was identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1 was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Exogenous modulation of NEAT-1 and/or BAP1 expression altered tumor cell phenotype and modulated sensitivity to gemcitabine. CONCLUSIONS: NEAT-1 is a downstream effector of gemcitabine sensitivity in CCA. The expression of BAP1 is a determinant of sensitivity to therapeutic drugs that can be exploited to enhance responses through combination strategies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-017-0587-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-25 /pmc/articles/PMC5264287/ /pubmed/28122578 http://dx.doi.org/10.1186/s12943-017-0587-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Parasramka, Mansi Yan, Irene K. Wang, Xue Nguyen, Phuong Matsuda, Akiko Maji, Sayantan Foye, Catherine Asmann, Yan Patel, Tushar BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
title | BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
title_full | BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
title_fullStr | BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
title_full_unstemmed | BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
title_short | BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
title_sort | bap1 dependent expression of long non-coding rna neat-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264287/ https://www.ncbi.nlm.nih.gov/pubmed/28122578 http://dx.doi.org/10.1186/s12943-017-0587-x |
work_keys_str_mv | AT parasramkamansi bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT yanirenek bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT wangxue bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT nguyenphuong bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT matsudaakiko bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT majisayantan bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT foyecatherine bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT asmannyan bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma AT pateltushar bap1dependentexpressionoflongnoncodingrnaneat1contributestosensitivitytogemcitabineincholangiocarcinoma |